FDA Accelerations, CMS Models, NICE RWE

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics are particularly timely given the convergence of regulatory and payment shifts we're seeing.

MarcusSame here. We're looking at FDA's accelerated approval expansion for neurodegenerative diseases — which could reshape evidence generation timelines. Then CMS's new oncology value-based payment model pilot — that's a major operational shift. Plus NICE's evolving real-world evidence framework — and what it signals for future appraisals. Finally, emerging HTA methodologies in Asia-Pacific — where innovation meets adaptation.

SaraThat second one about CMS's pilot is especially interesting to me — the budget implications of value-based models for high-cost oncology drugs could be transformative, but the operational complexity is significant.

MarcusExactly. Let's get into it.

MarcusStarting with FDA's accelerated approval pathway expansion. They've signaled greater flexibility for neurodegenerative diseases, particularly where traditional endpoints are challenging. This isn't about lowering standards but acknowledging the disease biology.

SaraI wonder if that's the full picture though. The part that gives me pause is how surrogate endpoints will be validated post-approval. The FDA's own guidance emphasizes the need for confirmatory trials, but the resource burden on companies is substantial.

MarcusThat's fair — and from the payer side, the risk of drugs entering the market without definitive evidence is a real concern. But what strikes me is the parallel development of companion diagnostics to mitigate that risk. It's creating a more nuanced evidence ecosystem.

SaraThe nuance is welcome, but the timeline pressure remains. I keep coming back to how this interacts with HTA bodies. If accelerated approvals come faster, how do payers adjust their value assessments? The evidence horizon is compressing, but the decision-making lag isn't.

MarcusThat connects to something I've been watching — the emergence of interim HTA assessments. Some bodies are now evaluating accelerated approvals with the understanding that confirmatory data is pending, essentially creating provisional reimbursement pathways. It's pragmatic but raises questions about sustainability.

SaraAbsolutely. And the budget impact of multiple provisional entries could strain systems. What's striking here is how this forces payers to become more comfortable with uncertainty. The traditional binary 'approve/deny' model is dissolving into something more dynamic.

MarcusExactly. The question becomes: can HTA methodologies adapt quickly enough? The FDA's move is smart, but the downstream consequences for value frameworks are still unfolding. We'll see how this plays out in the next 12 months.

MarcusShifting to CMS's oncology value-based payment model pilot. They're moving beyond traditional fee-for-service to outcomes-based contracting for high-cost cancer therapies. This is directly addressing the financial risk of ineffective treatments.

SaraThat's one read — I'd frame it slightly differently. What strikes me is the operational complexity CMS is introducing. The pilot requires real-world data capture and adjudication, which means new infrastructure and potential delays in patient access. The administrative burden could undermine the value proposition.

MarcusThat's a valid point. But what's interesting is how this connects to the broader shift toward value-based healthcare. CMS isn't just testing a payment model; they're creating a template for how to manage high-cost therapies across other areas. The precedent-setting nature is significant.

SaraThe precedent is important, but the practicalities matter too. I'm particularly curious about how they'll define 'success' for these contracts. If the endpoints aren't clinically meaningful, the model could incentivize the wrong outcomes. The part that gives me pause is the lack of standardized metrics across different cancer types.

MarcusThat's true — and it ties back to HEOR's role. Companies will need to develop more granular evidence packages to support these contracts. The HEOR team becomes central to designing the outcomes that matter. It's a shift from retrospective analysis to prospective evidence generation.

SaraExactly. And from the payer perspective, the budget impact depends entirely on how those outcomes are structured. If the bar is set too high, fewer drugs qualify; too low, and the financial risk remains. It's a delicate balance that HEOR teams must navigate carefully.

MarcusThe real test will be implementation. CMS has announced this pilot, but the operational details will determine whether it becomes a model or remains a niche experiment. We'll be watching how pharma responds with evidence strategies that align with these new payment structures.

MarcusNow to NICE's evolving real-world evidence framework. They're increasingly integrating RWE in technology appraisals, particularly for drugs where clinical trial data has limitations. This isn't about replacing RCTs but supplementing them.

SaraI'd push back slightly on that framing. What I'm seeing is NICE using RWE more critically — not just as supplemental evidence but as a primary source when it's robust enough. The question is whether the methodologies are keeping pace. The part that gives me pause is the heterogeneity of RWE sources and how they're weighted in decision-making.

MarcusThat's fair. NICE has been explicit about their evidence hierarchy, but the practical application is nuanced. What's interesting is how they're developing specific RWE evaluation criteria. It's a maturation of the approach, moving beyond 'is it real-world?' to 'how real-world is it?'.

SaraThe maturation is key, but the budget impact implications are substantial. If RWE supports wider access, it strains budgets; if it's used to restrict access, it conflicts with patient needs. The tension between methodological rigor and practical access is one the field hasn't fully worked out yet.

MarcusExactly. And this connects to the broader shift toward pragmatic clinical trials. Companies are designing studies that generate both regulatory and HTA-ready evidence simultaneously. It's a smarter use of resources, but requires early engagement with HTA bodies to align endpoints.

SaraThe early engagement is critical. I keep coming back to how NICE's framework influences global HTA. If they establish a gold standard for RWE integration, other bodies will follow. That could standardize evidence requirements across markets, which would be a significant win for efficiency.

MarcusThe standardization potential is exciting. But the challenge is maintaining flexibility. Diseases evolve, and evidence needs to adapt. NICE's framework will need to evolve too, which is why their iterative approach is smart. We'll see how they incorporate new data types like digital endpoints in the next iteration.

MarcusFinally, emerging HTA methodologies in Asia-Pacific. Countries like Japan, South Korea, and Australia are developing unique frameworks that blend international standards with local health system needs. This isn't just about adopting Western models but adapting them.

SaraThat's one read — I'd frame it slightly differently. What strikes me is the diversity within the region. Japan's focus on cost-minimization contrasts with Australia's health technology assessment processes. The part that gives me pause is how this fragmentation creates evidence challenges for companies operating across multiple markets.

MarcusThat's valid. The diversity is both a challenge and an opportunity. Companies can use this to test innovative evidence approaches in smaller markets before scaling globally. What's interesting is how some Asia-Pacific bodies are pioneering patient-centered methodologies that could influence global practices.

SaraThe patient-centered angle is important, but the budget realities are stark. Many Asia-Pacific systems have lower per-capita healthcare spending, so value thresholds are inherently different. The methodological shifts are often driven by cost constraints rather than innovation. That's a critical distinction from Western markets.

MarcusExactly. And this creates a tension between innovation access and system sustainability. Some countries are exploring risk-sharing agreements to bridge this gap, which requires more sophisticated HEOR evidence. It's forcing companies to develop tiered evidence strategies that account for different market contexts.

SaraThe tiered approach is necessary but resource-intensive. I'm particularly curious about how cross-border collaboration is developing. If Asia-Pacific bodies share methodologies, it could streamline access, but if they remain siloed, it increases the burden on manufacturers. The next 18 months will be telling.

MarcusThe collaboration potential is significant. We're seeing more joint scientific advice initiatives across the region, which could harmonize evidence requirements. But the pace varies, and companies must remain agile. The key is understanding that 'Asia-Pacific' isn't a monolith — each market requires tailored evidence strategies.

SaraA lot to think about today. I'll be watching how CMS's oncology payment model pilot evolves operationally — the administrative details will make or break its adoption.

MarcusSame — and for me the thread running through today is the growing interdependence between regulatory flexibility, payment innovation, and HTA adaptation. The traditional silos are dissolving, and HEOR teams are becoming the central connectors. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.